Financial Performance - The company's operating revenue for Q3 2024 was ¥716,338,343.26, a decrease of 9.11% compared to the same period last year[2] - The net profit attributable to shareholders was -¥27,453,286.21, representing a decline of 133.31% year-on-year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥27,004,706.62, down 133.17% from the previous year[2] - Total operating revenue for Q3 2024 was CNY 2,136,699,863.80, a decrease of 1.36% compared to CNY 2,166,125,568.45 in Q3 2023[15] - Net profit for Q3 2024 was CNY 50,835,668.99, down 35.06% from CNY 78,428,960.14 in Q3 2023[16] - The net profit attributable to shareholders of the parent company for Q3 2024 is CNY 15,841,198.32, compared to CNY 317,242,547.43 in the same period last year[17] - The total comprehensive income for Q3 2024 is CNY 22,845,948.88, with CNY 15,841,198.32 attributable to the parent company[17] - The basic and diluted earnings per share for Q3 2024 are both CNY 0.11, down from CNY 2.12 in the previous year[17] Assets and Liabilities - The total assets at the end of Q3 2024 were ¥4,705,861,156.23, a decrease of 2.27% from the end of the previous year[2] - The company's total assets decreased to CNY 4,705,861,156.23 from CNY 4,815,000,387.93, a decline of 2.28%[15] - Current liabilities totaled CNY 785,182,561.51, down from CNY 1,043,136,742.01, a decrease of 24.73%[15] - Long-term borrowings increased significantly to CNY 364,552,603.84 from CNY 94,806,722.63, representing a growth of 284.56%[15] - The total equity attributable to shareholders decreased by 3.21% to ¥2,218,116,822.82 compared to the end of the previous year[2] - The total equity attributable to shareholders decreased to CNY 2,218,116,822.82 from CNY 2,291,622,601.45, a decline of 3.19%[15] Cash Flow - Cash flow from operating activities for the year-to-date was ¥414,469,212.80, down 24.40% year-on-year[2] - Cash flow from operating activities for Q3 2024 is CNY 414,469,212.80, a decrease from CNY 548,228,797.85 in the same period last year[19] - Cash inflow from operating activities totals CNY 2,184,953,764.81, while cash outflow totals CNY 1,770,484,552.01[19] - Cash flow from investing activities shows a net outflow of CNY 613,278,600.03, compared to a net outflow of CNY 362,555,474.05 in the previous year[19] - Cash flow from financing activities results in a net outflow of CNY 126,944,951.80, compared to a net outflow of CNY 54,728,712.51 last year[19] - The net increase in cash and cash equivalents for Q3 2024 is CNY -325,754,339.03, compared to an increase of CNY 130,944,611.29 in the same period last year[20] - The ending balance of cash and cash equivalents is CNY 479,822,198.29, down from CNY 1,057,174,443.01 in the previous year[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 11,413[7] - Chengdu Puri Century Investment Co., Ltd. holds 35.91% of shares, totaling 53,729,585 shares, with 14,330,000 shares pledged[7] - Xu Xuyang, a natural person shareholder, holds 6.75% of shares, totaling 10,100,000 shares, with 7,000,000 shares pledged[7] - The top ten shareholders include entities such as Fushui Zhengxin Investment Partnership and Fushui Jinguang Qingcheng Investment Partnership, holding 4.01% and 3.11% respectively[7] - The top ten shareholders do not participate in margin financing or securities lending activities[11] - The company has not identified any other shareholders with related party relationships or acting in concert[11] - The company has not disclosed any other significant matters related to shareholders or shareholding changes[11] Operational Costs and Expenses - The company reported a significant increase in financial expenses by 34.05% to ¥61,638,478.21 due to new hospital leases[6] - Investment income dropped by 98.60% to ¥1,293,828.40, primarily due to the previous year's merger-related gains[6] - The company experienced a 34.30% increase in taxes and surcharges, totaling ¥5,579,082.07, mainly due to new property taxes[5] - Total operating costs amounted to CNY 2,058,379,113.42, up from CNY 1,846,235,666.59 in the previous year, reflecting an increase of 11.45%[16] - Research and development expenses for Q3 2024 were CNY 4,878,194.72, a decrease of 31.83% compared to CNY 7,155,122.27 in Q3 2023[16] Inventory and Receivables - The company reported a decrease in accounts receivable to CNY 100,681,983.67 from CNY 119,291,063.08, a reduction of 15.59%[15] - Inventory increased to CNY 162,949,240.82 from CNY 151,526,659.11, an increase of 7.93%[15] Audit and Reporting - The company has not undergone an audit for the Q3 2024 report[20] - The report indicates no changes in the number of restricted shares during the period[13] - The company has not reported any new strategies or significant developments in product or technology during this quarter[11]
普瑞眼科(301239) - 2024 Q3 - 季度财报